Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE3

Conditions

Maintenance Treatment of Peripheral T-cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan University Shanghai Cancer Center, Shanghai, China
Contact: Study coordinator (Rong Tao, MD & PhD) · rtao@shca.org.cn · 0086-21-64175590
Contact: Study coordinator (Chuanxu Liu, MD & PhD) · liuchuanxu@shca.org.cn · 0086-21-64175590

Study leads

Rong Tao, MD &PhD
Principal Investigator
Fudan University

View source on ClinicalTrials.gov